CKD , basic pathophysiology , anaesthesia considerations for patients with CKD , Prevention & treatment of AKI and other complications during anaesthesia in Known CKD patient, Anaesthesia consideration of non renal surgery in patients with post renal transplant

Reading File

Finding Sources

Reading File

Searching PubMed

chronic kidney disease anesthesia perioperative management

Reading File

Chronic Kidney Disease (CKD): Pathophysiology, Anaesthesia, AKI Prevention & Post-Transplant Management

PART 1 - Basic Pathophysiology of CKD

CKD is defined by a persistent (>3 months) reduction in GFR below 60 mL/min/1.73 m² and/or markers of kidney damage. It progresses through 5 stages (G1-G5) culminating in End-Stage Renal Disease (ESRD/G5) when GFR <15 mL/min/1.73 m².

Core Mechanisms of Progression

Mechanism	Detail
Hyperfiltration injury	Remaining nephrons hypertrophy and hyperfiltrate; glomerular hypertension causes further podocyte loss
Proteinuria	Filtered proteins are directly tubulotoxic; activate complement and inflammatory cascades
Fibrosis	TGF-β driven tubulo-interstitial fibrosis and glomerulosclerosis
RAAS activation	Angiotensin II promotes vasoconstriction, inflammation, and aldosterone-mediated sodium retention
Uremia	Accumulation of urea, creatinine, uremic toxins (indoxyl sulfate, p-cresyl sulfate) when GFR <10-15 mL/min

Systemic Effects of ESRD/Advanced CKD

Cardiovascular (most lethal - 35-40% of all ESRD deaths):

Hypertension: universally develops due to hyperreninemia, hypervolemia, and renal vasculature changes
Left ventricular hypertrophy (concentric, diastolic dysfunction) - most common cardiac abnormality
Dilated cardiomyopathy with systolic failure documented in ~40% of HD patients
Accelerated atherosclerosis and coronary artery disease (independent risk factor)
Pericardial disease: uremic pericarditis, effusion, constrictive pericarditis
Atrial fibrillation in up to 32% of ESRD patients
Cardiorenal syndrome: reciprocal decline in both cardiac and renal function

Haematologic:

Normochromic normocytic anaemia (EPO deficiency + iron deficiency + chronic inflammation + bone marrow fibrosis)
Platelet dysfunction (reduced vWF, factor VIII) → increased bleeding risk
Paradoxically, a hypercoagulable state may also develop (increased vascular thrombotic events)

Fluid, Electrolyte & Acid-Base:

Sodium and water retention → oedema, hypertension, pulmonary congestion
Hyperkalemia - most critical electrolyte disorder; life-threatening cardiac effects
Hyperphosphatemia, hypocalcaemia, hypermagnesaemia
Secondary hyperparathyroidism and renal osteodystrophy
High anion-gap metabolic acidosis (failure to excrete organic acids + impaired ammonium excretion)

Neurological (Uraemic Encephalopathy/Neuropathy):

Peripheral sensorimotor neuropathy
Autonomic neuropathy (gastroparesis, orthostatic hypotension)
Encephalopathy at severe uremia (asterixis, seizures, coma)

Pulmonary:

Pulmonary oedema (volume overload)
Uraemic pleuritis
Restrictive lung disease from chronic fluid overload

GI:

Gastroparesis (risk of aspiration)
Uraemic gastritis, nausea, impaired gastric emptying

Endocrine/Metabolic:

Impaired glucose tolerance
Secondary hyperparathyroidism → CKD-MBD (mineral and bone disorder)
Vitamin D deficiency (impaired 1α-hydroxylation)

Pharmacokinetic:

Reduced protein binding (uraemic toxins displace drugs from albumin)
Reduced volume of distribution (fluid shifts)
Impaired renal elimination of drugs and active metabolites

(Miller's Anesthesia, 10e, Chapter 56)

PART 2 - Anaesthesia Considerations for Patients with CKD

Preoperative Assessment

Key evaluations:

Baseline renal function - latest GFR, serum creatinine, BUN, electrolytes (especially K+, HCO3-)
Dialysis status - when was last dialysis? Aim to operate within 12-24 hours of dialysis to optimise volume/K+
Cardiovascular assessment - ECG (LVH, arrhythmias, peaked T waves of hyperkalaemia), echo if indicated, stress testing for high-risk patients
Haematology - FBC (anaemia severity), coagulation, bleeding time
Volume status - clinical assessment for euvolaemia
Medications - ACEi/ARB (hold on day of surgery), antihypertensives, anticoagulants, EPO, immunosuppressants
Airway - consider full stomach precautions due to gastroparesis

Absolute preoperative requirements before elective surgery:

K+ <5.5 mEq/L (ideally <5.0)
Corrected acidosis (pH >7.35)
Correction of significant anaemia (Hb >8-9 g/dL)
Blood pressure optimisation

Intraoperative Pharmacology in CKD/ESRD

Induction agents:

Agent	Consideration in CKD
Propofol	Safe; not significantly renally cleared; protein binding decreased (free fraction ↑) → reduce dose
Thiopental	Reduced protein binding → ↑ free fraction; use reduced dose
Ketamine	Largely hepatic metabolism; generally safe
Etomidate	Safe; no major renal concerns
Benzodiazepines	Active metabolites (lorazepam glucuronide) may accumulate; use cautiously

Volatile agents:

All modern volatiles (sevoflurane, desflurane, isoflurane) are safe in CKD
Sevoflurane - concern regarding compound A (nephrotoxic fluorinated vinyl ether in CO2 absorbers); clinically significant only at very low flows; generally safe at flow rates >2 L/min
Isoflurane/desflurane - preferred by some in severe CKD due to minimal metabolism

Neuromuscular Blockade (NMB):

Agent	Renal Elimination	CKD Consideration
Succinylcholine	Plasma cholinesterase	Avoid if K+ >5.5 (rises 0.5-1 mEq/L acutely); safe if K+ normal
Atracurium	Hofmann elimination + ester hydrolysis	Drug of choice - organ independent elimination; safe in ESRD
Cisatracurium	Same as atracurium	Also preferred; less histamine release than atracurium
Vecuronium	~30% renal	Prolongs in CKD; use with monitoring
Rocuronium	~33% renal	Duration prolonged; sugammadex reversal safe even in ESRD (multi-center trial confirmed safety)
Pancuronium	~85% renal	Avoid in severe CKD - marked prolongation

Opioids:

Agent	Consideration
Fentanyl	Hepatic; generally safe; preferred for short procedures
Remifentanil	Ester hydrolysis; completely organ-independent; ideal in severe CKD
Morphine	Active metabolite M6G accumulates in renal failure → prolonged CNS depression; use cautiously
Hydromorphone	Metabolite accumulation in renal failure (Hydromorphone-3-glucuronide); use cautiously
Meperidine	Normeperidine (active toxic metabolite) accumulates → seizures; avoid in CKD
Tramadol	Active metabolites accumulate; avoid or reduce dose
Buprenorphine	Partial hepatic; generally safer in CKD

(Barash Clinical Anesthesia, 9e; Miller's Anesthesia, 10e)

NSAIDs:

Contraindicated in all stages of CKD - reduce renal prostaglandin synthesis, precipitate acute-on-chronic renal failure, worsen hypertension, cause fluid retention

ACE inhibitors/ARBs:

Generally held on the morning of surgery
Can cause intraoperative refractory hypotension (especially with induction)

Antibiotics in CKD:

Renally-cleared antibiotics (aminoglycosides, vancomycin, carbapenems) require dose adjustment
Avoid nephrotoxic combinations (aminoglycosides + vancomycin if possible)

Regional vs General Anaesthesia in CKD

Regional anaesthesia advantages:

Avoids systemic drug accumulation
Better postoperative analgesia (reduces opioid requirements)
Maintains renal perfusion better than some general techniques
Preferred for procedures where applicable

Special considerations for regional:

Coagulopathy must be assessed first (platelet dysfunction in uremia, possible anticoagulant use)
Arteriovenous fistula protection - pad and protect the fistula arm; never place BP cuff or IV on fistula arm
Autonomic neuropathy increases risk of hypotension with neuraxial block

Intraoperative Monitoring in CKD

Standard ASA/AAGBI monitoring at minimum
Invasive arterial line for beat-to-beat BP in severe CKD/ESRD
Central venous access if needed (avoid subclavian on dialysis access side)
Neuromuscular monitoring is mandatory when using NMB
Urine output monitoring (though intraoperative oliguria does not reliably predict AKI - see Part 3)
Temperature monitoring (hypothermia shifts K+ and worsens coagulopathy)
Blood glucose monitoring (impaired glucose tolerance)

Fluid Management

Avoid saline overload (worsens hyperchloremic acidosis and hyperkalemia)
Prefer balanced crystalloids (Plasmalyte, Hartmann's/Lactated Ringer's) - note: Hartmann's contains 4 mEq/L K+ which is generally safe in non-hyperkalemic patients
Avoid starches (HES solutions) - associated with AKI
Target euvolaemia; avoid hypovolaemia (reduces GFR) and hypervolaemia (pulmonary oedema in patients with limited reserve)

Positioning

Protect fistulae and shunts
Careful padding (peripheral neuropathy = pressure injury risk)
Frequent position checks

PART 3 - Prevention & Treatment of AKI During Anaesthesia in Known CKD Patients

CKD is a major independent risk factor for perioperative AKI. Approximately one-quarter of hospital-acquired renal failure occurs in the perioperative period, carrying high mortality - especially after cardiac and major vascular surgery.

KDIGO Staging of AKI

Stage	Serum Creatinine	Urine Output
1	×1.5-1.9 baseline within 7 days OR ↑≥0.3 mg/dL within 48h	<0.5 mL/kg/h for 6-12h
2	×2.0-2.9 baseline	<0.5 mL/kg/h for ≥12h
3	×3 baseline OR sCr ≥4 mg/dL OR initiation of RRT	<0.3 mL/kg/h for ≥24h OR anuria ≥12h

(Bailey & Love's Surgery, 28e)

Causes of Perioperative AKI

Pre-renal: Hypovolaemia (haemorrhage, dehydration, bowel prep), hypotension, low cardiac output, excessive vasodilators

Intrinsic/Renal:

Inflammation and sepsis
Pre-existing CKD and comorbidities (diabetes, obesity)
Endogenous nephrotoxins: myoglobin (rhabdomyolysis), haemoglobin (haemolysis)
Exogenous nephrotoxins: contrast agents, NSAIDs, aminoglycosides, amphotericin

Post-renal: Obstruction (ureteric injury, catheter blockage in context of prostatic disease)

Prevention Strategies

1. Identify high-risk patients:

Pre-existing CKD, diabetes, heart failure, >65 years, emergency surgery
Cardiac and major vascular surgery patients
Patients receiving nephrotoxic drugs preoperatively

2. Haemodynamic optimisation:

Maintain MAP ≥65 mmHg intraoperatively (higher targets in CKD, e.g. MAP ≥75-80)
Avoid hypotension - the single most modifiable perioperative risk factor for AKI
Goal-directed fluid therapy (GDT) using stroke volume variation, oesophageal Doppler, or PICCO rather than targeting CVP alone
Treat sepsis early (antibiotics within 1 hour, vasopressors if needed)

3. Volume management:

Maintain normovolaemia
Intraoperative oliguria does NOT reliably predict AKI - do NOT reflexively give large fluid boluses for oliguria (Bailey & Love's Surgery, 28e)
Avoid excessive volume (dilutional anaemia, pulmonary oedema, abdominal compartment)

4. Avoid nephrotoxins:

NSAIDs - absolutely avoid
Aminoglycosides - use only when essential; single daily dosing; monitor levels
IV contrast - use minimum volume, iso-osmolar agents; N-acetylcysteine ± sodium bicarbonate pre-hydration if essential
Avoid HES solutions (hydroxyethyl starch)

5. Avoid unnecessary blood transfusions:

Cell-salvage, antifibrinolytics (tranexamic acid) when appropriate
Old stored blood is associated with free haemoglobin-mediated nephrotoxicity

6. Prompt treatment of infection/sepsis

7. Nutritional support - avoid catabolism; normovolaemic protein administration

8. Monitoring:

Creatinine and urine output every 6-12 hours in high-risk perioperative patients
NGAL, cystatin C (early AKI biomarkers, though not universally available)

Treatment of Established Perioperative AKI

Intervention	Detail
Identify and treat the cause	Fluid resuscitation if pre-renal; relieve obstruction if post-renal; stop nephrotoxins
Haemodynamic resuscitation	Target MAP ≥65 (higher in CKD); vasopressors (noradrenaline first-line in vasodilatory shock)
Fluid	Volume-responsive patients: crystalloid resuscitation; avoid fluid excess once unresponsive
Diuretics	Furosemide may be used for volume management and uraemic symptom relief; does NOT prevent or improve AKI outcome
Renally dose-adjust medications	Review all drug doses against current GFR
Glycaemic control	Target glucose 140-180 mg/dL; avoid hypoglycaemia
Renal Replacement Therapy (RRT)	Indications: refractory hyperkalaemia (K+>6.5), refractory acidosis (pH<7.1), volume overload unresponsive to diuretics, uremic encephalopathy/pericarditis; continuous RRT (CRRT) preferred in haemodynamically unstable patients
Prevent secondary insults	Maintain perfusion pressure; treat infection; avoid contrast

(Bailey & Love's Surgery, 28e; Miller's Anesthesia, 10e)

PART 4 - Anaesthesia for Non-Renal Surgery in Post-Renal Transplant Patients

This is a complex area requiring understanding of: residual graft function, immunosuppression effects, drug interactions, and cardiovascular risk.

Understanding the Post-Transplant Patient

Allograft function:

GFR typically deteriorates by 1.4-2.4 mL/min/year after transplant
Many long-term transplant recipients have a GFR comparable to CKD Stage 2-3
Treat as a CKD patient for anaesthetic drug selection
Creatinine may be elevated even with good function (donor baseline, graft characteristics)

Cardiovascular risk remains high:

Accelerated atherosclerosis continues post-transplant (immunosuppressant side effects: tacrolimus/cyclosporine - hypertension; corticosteroids - dyslipidaemia, diabetes)
Standard cardiac risk stratification applies; stress testing may be needed

Immunosuppression Regimens and Anaesthetic Implications

Post-transplant patients are typically maintained on triple therapy:

Drug Class	Examples	Anaesthetic Concerns
Calcineurin inhibitors (CNI)	Tacrolimus, Cyclosporine	Nephrotoxic; drug interactions via CYP3A4; narrow therapeutic window; avoid nephrotoxins; tacrolimus neurotoxicity (seizures) at toxic levels
Antimetabolites	Azathioprine, Mycophenolate	Azathioprine inhibits plasma cholinesterase → prolonged succinylcholine effect; mycophenolate - GI side effects
Corticosteroids	Prednisolone	Adrenal suppression - perioperative steroid supplementation required ("stress dosing"); hyperglycaemia; poor wound healing; susceptibility to infection
mTOR inhibitors	Sirolimus, Everolimus	Poor wound healing; avoid in cases with high wound infection risk

Critical rule: Never omit or significantly delay immunosuppression doses perioperatively - acute rejection can be precipitated. If oral route is unavailable, IV equivalents must be used.

Preoperative Assessment of the Post-Transplant Patient

Graft function - recent creatinine, GFR, electrolytes, urinalysis
Immunosuppression drug levels - tacrolimus/cyclosporine trough levels (nephrotoxicity risk if supratherapeutic; rejection risk if sub-therapeutic)
Cardiovascular assessment - extensive workup often needed (hypertension, IHD, LVH)
Infection screen - opportunistic infection history; screen for CMV, EBV; avoid immunomodulatory transfusions
Metabolic - glucose control (steroid-induced diabetes), bone density (osteoporosis from steroids)
Drug interactions - anaesthetic agents interacting with CYP3A4 substrates
Haematology - anaemia, leukopenia, thrombocytopenia (from azathioprine/mycophenolate)

Drug Selection for Non-Renal Surgery in Transplant Recipients

Neuromuscular blocking agents:

Atracurium/cisatracurium preferred (Hofmann elimination; organ-independent)
Succinylcholine: check K+ first; azathioprine inhibits plasma cholinesterase → prolonged block
Vecuronium/rocuronium: use with careful monitoring; duration may be prolonged if graft function is reduced
Sugammadex: safe for reversal of rocuronium/vecuronium in transplant patients

Anaesthetic agents:

Propofol, etomidate, ketamine: all acceptable
Sevoflurane: safe at adequate fresh gas flows; moderate fluoride load acceptable if graft GFR reasonably preserved
Isoflurane/desflurane: preferred alternatives in compromised graft function

Opioids:

Fentanyl or remifentanil preferred
Avoid morphine (M6G accumulation if graft GFR reduced)
Avoid meperidine (normeperidine toxicity)

Analgesics:

NSAIDs: contraindicated - particularly dangerous as they reduce prostaglandin-mediated afferent arteriolar tone in the transplanted kidney, which relies on this mechanism more than native kidneys
Paracetamol/acetaminophen: safe; preferred first-line
Regional techniques: excellent option; reduces opioid requirements

Antibiotics:

Aminoglycosides + CNIs = additive nephrotoxicity; avoid if possible
Interaction: azithromycin, erythromycin, fluconazole inhibit CYP3A4 → ↑ tacrolimus/cyclosporine levels
Use antibiotic combinations with minimal nephrotoxic potential

Intraoperative Considerations

Haemodynamic management:

Maintain adequate perfusion pressure to the graft (MAP ≥75-80 mmHg preferred in transplant recipients)
Avoid hypotension - ischaemia-reperfusion injury to the already-vulnerable allograft
Adrenergic vasopressors are relatively avoided due to vasoconstrictive effects on the denervated graft; however, noradrenaline can be used cautiously when systemic hypotension must be treated - the risk of untreated hypotension outweighs graft vasoconstriction
Volume expansion with balanced crystalloids preferred

Blood transfusion:

Transplant recipients are often anaemic (erythropoietin therapy may be ongoing)
Transfusion triggers similar to general population (Hb ~7-8 g/dL unless cardiovascular compromise)
If CMV-negative status: use CMV-negative or leukodepleted blood products (cytomegalovirus transmission risk)
Leucocyte-depleted blood to reduce alloimmunisation

Fluid management:

Avoid hypovolaemia (graft ischaemia risk)
Avoid hypervolaemia (limited reserve if graft GFR reduced, cardiac dysfunction from prior ESRD)
GDT strategies can guide intraoperative resuscitation

Graft site considerations:

The kidney is transplanted retroperitoneally in the iliac fossa (right or left)
Intra-abdominal pressure during laparoscopic procedures may impair graft perfusion - limit insufflation pressure (<12 mmHg) and monitor urine output
Avoid positioning that kinks the graft vessels

Postoperative care:

Monitor creatinine closely post-operatively
Continue immunosuppression without interruption
Wound healing may be impaired (steroids, mTOR inhibitors)
Infection surveillance (immunocompromised patient)
Pain management: multimodal analgesia with paracetamol, regional techniques, gabapentinoids; minimize opioids; strict avoidance of NSAIDs

Steroid Cover ("Stress Dosing")

Patients on long-term corticosteroids have HPA axis suppression and cannot mount an adequate cortisol response to surgical stress:

Minor surgery (local anaesthesia): usual oral dose only
Moderate surgery: hydrocortisone 25-50 mg IV at induction + 25-50 mg every 8h for 24h
Major surgery: hydrocortisone 50-100 mg IV at induction + 50 mg every 8h for 48-72h, then taper to normal dose

Summary Table

Topic	Key Points
CKD Pathophysiology	Multi-system disease; CVS most lethal; hyperK+/acidosis/anaemia are critical
Anaesthesia in CKD	Prefer atracurium/cisatracurium; avoid morphine/meperidine; adjust doses; protect fistula; correct K+ pre-op
AKI Prevention	Haemodynamic optimisation (MAP >65), avoid nephrotoxins, GDT fluids, no NSAIDs, treat sepsis early
AKI Treatment	Treat cause, haemodynamic support, RRT for refractory K+/acidosis/volume overload
Post-Transplant Non-Renal Surgery	Continue immunosuppression; steroid stress dosing; avoid NSAIDs; prefer atracurium; protect graft perfusion; CMV-safe blood; watch drug interactions with CNIs

Sources:

Miller's Anesthesia, 10e - Chapter 56: Anesthesia for Abdominal Organ Transplantation, Pathophysiology of ESRD, Kidney Transplant Anaesthesia
Bailey and Love's Short Practice of Surgery, 28e - Chapter 24: Perioperative AKI, KDIGO Staging
Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e - Drug pharmacology in renal failure
Saran S, Kharat A, et al. Anaesthesia Challenges in Patients With Chronic Kidney Disease - Cureus, 2025 (PMID: 41058824)

This is a shared conversation. Sign in to Orris to start your own chat.